<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Noticias para Experto en Trombosis</title>
<link href="http://www.expertoentrombosis.com" ></link>
<id>urn:uuid:810cd04d-0763-425b-2b0d-ca4b437ac302</id>
<updated>2012-05-20T04:45:05+02:00</updated>
<author><name>Noticias para Experto en Trombosis</name>
</author>
<entry>
<title>AHA&#58; Post&#45;MI Warfarin Underused in Afib</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Post-MI+Warfarin+Underused+in+Afib#news948" ></link>
<id>urn:uuid:47318016-5da1-f74d-bd30-f303e221808f</id>
<updated>2010-11-22T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Less than half of heart attack patients with recent atrial fibrillation get warfarin at discharge, according to a registry study. ]]></summary>
</entry>
<entry>
<title>AHA&#58; Warfarin Use Related to Several Factors  </title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Warfarin+Use+Related+to+Several+Factors#news947" ></link>
<id>urn:uuid:e75351de-2865-06a5-7824-0a086d4fa694</id>
<updated>2010-11-22T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Many factors aside from the CHADS2 stroke risk score appear to contribute to the decision to give warfarin to patients newly diagnosed with atrial fibrillation, researchers found. ]]></summary>
</entry>
<entry>
<title>AHA&#58; No Link Between Insulin Resistance and Afib </title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+No+Link+Between+Insulin+Resistance+and+Afib#news946" ></link>
<id>urn:uuid:f698aaca-425f-8432-a2a0-58344bfddab4</id>
<updated>2010-11-22T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Insulin resistance is not associated with the development of atrial fibrillation, according to an analysis of the Framingham Heart Study. ]]></summary>
</entry>
<entry>
<title>AHA&#58; Stroke History Tied to Renal Function in Afib</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Stroke+History+Tied+to+Renal+Function+in+Afib#news945" ></link>
<id>urn:uuid:28cc5a0a-ca89-07d8-aab0-c1fc30dc233b</id>
<updated>2010-11-22T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[In patients who have undergone cardioversion for atrial fibrillation, impaired renal function appears to be associated with a history of stroke, researchers found. ]]></summary>
</entry>
<entry>
<title>BMS&#44; Pfizer halt Apixaban Phase 3 APPRAISE&#45;2 trial</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=BMS%2C+Pfizer+halt+Apixaban+Phase+3+APPRAISE-2+trial#news944" ></link>
<id>urn:uuid:3ab55912-29e5-a9f5-76da-7861eca7d52a</id>
<updated>2010-11-19T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[There was clear evidence of a clinically important increase in bleeding among patients randomised to Apixaban, which was not offset by clinically meaningful reductions in ischemic events.]]></summary>
</entry>
<entry>
<title>AHA&#58; Guidelines Not a Factor in Warfarin Choices</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Guidelines+Not+a+Factor+in+Warfarin+Choices#news943" ></link>
<id>urn:uuid:20255021-4f7b-9a10-2b55-26dddfebda3d</id>
<updated>2010-11-19T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Clinicians do not seem to be relying on the recommended stroke risk score to prescribe warfarin for patients with atrial fibrillation, researchers found.]]></summary>
</entry>
<entry>
<title>AHA&#58; Hidden Arrhythmias May Increase Stroke Risk</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Hidden+Arrhythmias+May+Increase+Stroke+Risk#news942" ></link>
<id>urn:uuid:1c514940-db6f-82cb-2bd1-83d7ee4c074f</id>
<updated>2010-11-19T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Asymptomatic atrial arrhythmias detected by a pacemaker or implantable cardioverter-defibrillator are associated with an increased stroke risk, a prospective cohort study showed.]]></summary>
</entry>
<entry>
<title>Major Study Shows Ability of New Agent to Prevent Strokes in Patients with Atrial Fibrillation</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Major+Study+Shows+Ability+of+New+Agent+to+Prevent+Strokes+in+Patients+with+Atrial+Fibrillation#news941" ></link>
<id>urn:uuid:def45741-6159-21b5-4e67-f3ef64518eab</id>
<updated>2010-11-19T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[In the primary result from the largest double-blind study ever completed to assess a drug’s effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be superior to warfarin, the current standard for treatment of atrial fibrillation, while patients in the study were taking study drug.]]></summary>
</entry>
<entry>
<title>Omega&#45;3 Supplements Won&#39;t Fight Irregular Heartbeat</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Omega-3+Supplements+Won%27t+Fight+Irregular+Heartbeat#news940" ></link>
<id>urn:uuid:81433d99-a9cf-3690-cf36-b5265d9ca94c</id>
<updated>2010-11-17T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Omega-3 fatty acid supplements don't cut back on recurrences of atrial fibrillation, a type of irregular heartbeat that can cause stroke, new research suggests.]]></summary>
</entry>
<entry>
<title>GRAVITAS&#58; High&#45;dose clopidogrel did not improve post&#45;PCI outcomes</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=GRAVITAS%3A+High-dose+clopidogrel+did+not+improve+post-PCI+outcomes#news939" ></link>
<id>urn:uuid:faf96b29-d0b7-7623-4298-a54cdf9e9333</id>
<updated>2010-11-17T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[High-dose clopidogrel was not superior to the standard dose in reducing CV death, non-fatal MI or stent thrombosis following PCI among patients with high residual platelet reactivity.]]></summary>
</entry>
<entry>
<title>Electrical Cardioversion Beneficial for Older Adults With Atrial Fibrillation&#58; Presented at AHA</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Electrical+Cardioversion+Beneficial+for+Older+Adults+With+Atrial+Fibrillation%3A+Presented+at+AHA#news938" ></link>
<id>urn:uuid:c0a735f6-60ac-57e4-bf1f-22a0b967107e</id>
<updated>2010-11-16T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Electrical cardioversion significantly reduces the risk of death in older patients with atrial fibrillation, according to a study presented here today at the American Heart Association (AHA) Scientific Sessions 2010.]]></summary>
</entry>
<entry>
<title>For Coronary Patients&#44; H2RA Plus Clopidogrel Spikes Risk</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=For+Coronary+Patients%2C+H2RA+Plus+Clopidogrel+Spikes+Risk#news937" ></link>
<id>urn:uuid:89dfacb6-7826-c56a-804b-0b2b68523448</id>
<updated>2010-11-16T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The concomitant use of a histamine2-receptor antagonist and clopidogrel for patients with prior acute coronary syndrome more than doubles the risk of rehospitalization or death compared to treatment with clopidogrel only, according to research published in the October issue of Gastroenterology.]]></summary>
</entry>
<entry>
<title>Effect of Clopidogrel in Patients With ACS Appears Consistent Regardless of CYP2C19 Genotype&#58; Presented at CCC</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Effect+of+Clopidogrel+in+Patients+With+ACS+Appears+Consistent+Regardless+of+CYP2C19+Genotype%3A+Presented+at+CCC#news936" ></link>
<id>urn:uuid:f8fd5073-f8a9-7065-6012-17394964e1ee</id>
<updated>2010-11-16T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[The effect of clopidogrel compared with placebo in patients with acute coronary syndromes (ACS) or atrial fibrillation (AF) appears to be consistent irrespective of CYP2C19 genotype, according to research presented here October 28 at the 2010 Canadian Cardiovascular Congress (CCC).]]></summary>
</entry>
<entry>
<title>Clopidogrel and the Reduced&#45;Function CYP2C19 Genetic Variant</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Clopidogrel+and+the+Reduced-Function+CYP2C19+Genetic+Variant#news935" ></link>
<id>urn:uuid:0874454c-e02c-1148-5685-f74f30f4ae3f</id>
<updated>2010-11-16T00:00:00+01:00</updated>
<summary type="html" ><![CDATA[Effective platelet inhibition has become a cornerstone in the management of patients with acute coronary syndrome (ACS). Yet studies have demonstrated that the therapeutic response of clopidogrel is variable among patients, and low or incomplete platelet inhibition has been associated with increased risk for major adverse cardiovascular events.]]></summary>
</entry>
<entry>
<title>Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+of+Recurrence+After+a+First+Episode+of+Symptomatic+Venous+Thromboembolism+Provoked+by+a+Transient+Risk+Factor#news934" ></link>
<id>urn:uuid:29561988-80c6-6e4d-c142-9d468e5bb405</id>
<updated>2010-10-27T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[The risk of recurrence is low if VTE is provoked by surgery, intermediate if provoked by a nonsurgical risk factor, and high if unprovoked. These risks affect whether patients with VTE should undergo short-term vs indefinite treatment.]]></summary>
</entry>
<entry>
<title>Home Monitoring of Blood&#45;Thinner Use Appears Effective </title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Home+Monitoring+of+Blood-Thinner+Use+Appears+Effective#news933" ></link>
<id>urn:uuid:2eb02f4d-f81a-563f-58ae-4bf8ddb22206</id>
<updated>2010-10-26T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[The study, which is published in the Oct. 21 issue of the New England Journal of Medicine, found that weekly home tests were similarly effective to monthly clinic testing for patients taking warfarin therapy. ]]></summary>
</entry>
<entry>
<title>Patient&#45;Level Meta&#45;analysis&#58; Effect of Measurement Timing&#44; Threshold&#44; and Patient Age on Ability of d&#45;Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Patient-Level+Meta-analysis%3A+Effect+of+Measurement+Timing%2C+Threshold%2C+and+Patient+Age+on+Ability+of+d-Dimer+Testing+to+Assess+Recurrence+Risk+After+Unprovoked+Venous+Thromboembolism#news932" ></link>
<id>urn:uuid:7630361d-d661-daa2-672a-62264fd84f98</id>
<updated>2010-10-20T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[In patients with a first unprovoked venous thromboembolism (VTE), an elevated d-dimer level after anticoagulation is stopped is a risk factor for recurrent VTE.]]></summary>
</entry>
<entry>
<title>Increasing Catheter Size Tied to Greater Thrombosis Risk </title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Increasing+Catheter+Size+Tied+to+Greater+Thrombosis+Risk#news931" ></link>
<id>urn:uuid:15ee28a5-fab0-40ea-7620-ddb6f6a09369</id>
<updated>2010-10-07T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[Previous deep vein thrombosis and increasing catheter size are related to an increased risk for peripherally inserted central catheter-associated deep vein thrombosis, according to a study in the October issue of Chest. ]]></summary>
</entry>
<entry>
<title>Pharmacists&#39; involvement in warfarin therapy reduced total bleeding by half</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Pharmacists%27+involvement+in+warfarin+therapy+reduced+total+bleeding+by+half#news930" ></link>
<id>urn:uuid:5a73da69-8584-630f-50d3-0f0020cbecd2</id>
<updated>2010-10-07T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[Results from a meta-analysis conducted by researchers in Thailand, Australia and the United States showed that pharmacist-participated warfarin management reduced total bleeding by nearly 50% compared with usual care. ]]></summary>
</entry>
<entry>
<title>In the absence of a central venous catheter&#44; risk of venous thromboembolism is low in critically injured children&#44; adolescents&#44; and young adults&#58; Evidence from the National Trauma Data Bank </title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=In+the+absence+of+a+central+venous+catheter%2C+risk+of+venous+thromboembolism+is+low+in+critically+injured+children%2C+adolescents%2C+and+young+adults%3A+Evidence+from+the+National+Trauma+Data+Bank#news929" ></link>
<id>urn:uuid:0c58c775-d14f-9d3a-6adf-a41af81f8b20</id>
<updated>2010-10-07T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[Venous thromboembolism is rare in young critical care trauma patients, even older adolescents. However, venous thromboembolism prophylaxis may need to be considered only in critically injured adolescents and young adults with a continuing need for central venous access. ]]></summary>
</entry>
<entry>
<title>Elevated C&#45;Reactive Protein a Risk Factor for Early Stroke&#45;Related Deep Venous Thrombosis&#58; Presented at EFNS</title>
<link href="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Elevated+C-Reactive+Protein+a+Risk+Factor+for+Early+Stroke-Related+Deep+Venous+Thrombosis%3A+Presented+at+EFNS#news928" ></link>
<id>urn:uuid:caee7004-fc93-c44b-a21b-902b9860c4d1</id>
<updated>2010-09-30T00:00:00+02:00</updated>
<summary type="html" ><![CDATA[Patients who have elevated serum C-reactive protein (CRP) at stroke onset have a higher risk of developing deep venous thrombosis (DVT), and could benefit from DVT prophylaxis, according to a study reported at the 14th Congress of the European Federation of Neurological Societies (EFNS).]]></summary>
</entry>
</feed>
